Josep Carreras Leukaemia Research Institute, Hospital Clínic de Barcelona, Universitat de Barcelona, Barcelona, Spain.
Hemostasis and Erythropathology Laboratory, Hematopathology, Department of Pathology, Centre de Diagnòstic Biomèdic (CDB), Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain.
J Cell Mol Med. 2023 May;27(9):1227-1238. doi: 10.1111/jcmm.17712. Epub 2023 Apr 4.
Graft-versus-host disease (GVHD) is a complication of allogeneic haematopoietic cell transplantation. Endothelial injury is crucial as pathophysiological substrate for GVHD. GVHD first-line treatment is high-dose corticosteroids, although some patients are steroid-refractory. Through the present study, we compared the endothelial proteomic profiles in response to serum from steroid-refractory acute GVHD (SR-aGVHD) and steroid-sensitive acute GVHD (SS-aGVHD) patients. Blood samples from SR-aGVHD (n = 4) and SS-aGVHD (n = 8) patients were collected at aGVHD diagnosis. Endothelial cell cultures were exposed (48 h) to patients' serum. Protein extraction and proteomic analysis were performed. Differences were statistically evaluated by multivariate analysis. Forty-four proteins contributed to separate all samples into the two study groups, among which 15 participated significantly (p < 0.05), 10 exhibiting a fold change >1.2. Differentially expressed proteins were mainly associated with oxidative phosphorylation (Cytochrome C oxidase subunit 6B1, CX6B1), inflammation and angiogenesis (Apolipoprotein D, APOD), cell survival (Rapamycin-insensitive companion of mTOR, RICTR), and oxidative stress (Riboflavin kinase, RIFK). This pilot study used a novel approach to distinguish the aGVHD response to steroid treatment. The proteins differentially expressed could constitute potential biomarkers for steroid-treatment response. These findings signify a step forward to identify the mechanisms of response to steroids, of high clinical relevance considering the SR-aGVHD elevated mortality.
移植物抗宿主病(GVHD)是异基因造血细胞移植的一种并发症。内皮细胞损伤是 GVHD 的病理生理基础。GVHD 的一线治疗是大剂量皮质类固醇,但有些患者对皮质类固醇耐药。通过本研究,我们比较了对皮质类固醇耐药性急性 GVHD(SR-aGVHD)和皮质类固醇敏感性急性 GVHD(SS-aGVHD)患者血清的内皮蛋白组特征。在 aGVHD 诊断时采集 SR-aGVHD(n=4)和 SS-aGVHD(n=8)患者的血液样本。将内皮细胞培养物暴露于患者血清中(48 小时)。进行蛋白质提取和蛋白质组分析。通过多元分析评估差异的统计学意义。有 44 种蛋白质将所有样本分为两组,其中 15 种蛋白质差异有统计学意义(p<0.05),10 种蛋白质的倍数变化>1.2。差异表达的蛋白质主要与氧化磷酸化(细胞色素 C 氧化酶亚基 6B1,CX6B1)、炎症和血管生成(载脂蛋白 D,APOD)、细胞存活(雷帕霉素无反应伴侣的 mTOR,RICTR)和氧化应激(核黄素激酶,RIFK)有关。这项初步研究使用了一种新方法来区分 aGVHD 对皮质类固醇治疗的反应。差异表达的蛋白质可能构成皮质类固醇治疗反应的潜在生物标志物。这些发现标志着在确定对类固醇的反应机制方面向前迈进了一步,考虑到 SR-aGVHD 死亡率较高,这具有很高的临床相关性。